ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Oncolytic HSV-1 Expressing IL-12 and IL-15/IL-15-receptor Alpha VG2025

Also written as “VG2025” and “Recombinant Human IL12/15 Dual-Regulated Oncolytic HSV-1 Injection”.

Its studies are mostly in Cholangiocarcinoma · Neuroendocrine Tumors, led by 3 companies.

Drug pageOncolytic HSV-1 Expressing IL-12 and IL-15/IL-15-receptor Alpha VG2025: every studyAll 4 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 2, since Jul 15, 20223 company-led studies, 3 open or runningNext primary completion: Jan 18, 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Shanghai Virogin Biotechits history only11 open or runningphase 1since Jul 15, 2022Jul 15, 2022none ahead
Virogin Biotech Canadaits history only11 open or runningphase 1since Feb 9, 2022Feb 9, 2022none ahead
Virogin Biotechits history only11 open or runningphase 2since Apr 1, 2026Apr 1, 2026Jan 18, 2028phase 2 · NCT07522476

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of every company. Pick one to see its own:

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 9, 2022First study: phase 1 study in Neuroendocrine TumorsNew to Virogin Biotech CanadaVirogin Biotech Canada · NCT05266612 · 12 planned · United States
  2. Jul 15, 2022Shanghai Virogin Biotech’s first study: phase 1 study in Advanced Malignant Solid TumorNew to Shanghai Virogin BiotechShanghai Virogin Biotech · NCT05477849 · 30 planned · China
  3. Apr 1, 2026Virogin Biotech’s first study: phase 2 study in CholangiocarcinomaNew to Virogin BiotechVirogin Biotech · NCT07522476 · 30 planned · China

Ahead

  1. Jan 18, 2028Primary completion: phase 2 study in CholangiocarcinomaVirogin Biotech · NCT07522476

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07522476Cholangiocarcinoma · China2RecruitingVirogin BiotechJan 18, 202830
NCT05477849Advanced Malignant Solid Tumor · China1RecruitingShanghai Virogin BiotechOct 31, 202530
NCT05266612Neuroendocrine Tumors · United States1RecruitingVirogin Biotech CanadaDec 31, 202412

How it is read

Names in the registry

  • “VG2025”, 2 entries
  • “Recombinant Human IL12/15 Dual-Regulated Oncolytic HSV-1 Injection”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.